Hepatitis C virus (HCV) infection remains a global health problem. Previously, the
prevalence of NS5A resistance-associated substitutions (RASs) to elbasvir, a new direct …

Relevant resistance-associated substitutions (RASs) to elbasvir, the new HCV NS5A
inhibitor, may limit its efficacy and lead to virological failure in HCV-GT1a-infected patients …

Direct-acting antivirals (DAAs) targeting NS5A are broadly effective against hepatitis C virus
(HCV) infections, but sustained virological response rates are generally lower in patients …

Objectives Genetic variability in NS5A is associated with different levels of resistance to the
currently licensed NS5A inhibitors. The aim of this study was to detect NS5A inhibitor …

Resistance-associated substitutions (RASs) to the new HCV NS5A inhibitor elbasvir may
limit its efficacy and lead to virological failure in HCV-GT1a-infected patients. There are no …

Direct acting antiviral (DAA) therapy against hepatitis C virus (HCV) increases sustained
virologic response rates. Nevertheless, drug resistance has occasionally been associated …

Background: Little is known about the frequency or geographic distributions of naturally
occurring resistance-associated substitutions (RASs) in the nonstructural protein 5A (NS5A) …

The presence of resistance‐associated substitutions (RASs) at NS5A region might
compromise the efficacy of Direct Acting Antiviral agents (DAAs). HCV resistance at NS5A …

Natural resistance-associated substitutions (RASs) are reported with highly variable
prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large …

Resistance associated substitutions (RASs) can reduce the efficacy of direct-acting antiviral
agents (DAAs) targeting hepatitis C virus (HCV) and lead to treatment failure. Clinical data of …